Commercial funding received

Received by the Nuffield Department of Population Health, University of Oxford, since 2005

3-C trial of transplant rejection (2009-2017)

          Pfizer: £530K

          Novartis: £350K

ACE trial of acarbose (2008-2017)

Bayer: £135K *

ASCEND trial of aspirin and fish oils (2004-2017)

Abbott/Solvay/Mylan: £2.1M plus drug supply Bayer: £1.8M plus drug supply

ASCEND PLUS (2021 – ongoing)

Novo Nordisk A/S: £39.4M

Assessing the potential for SenseCam to fight the current global health crises of increasing obesity and physical inactivity (2010-2013)

Microsoft: £69K

ATLAS trial of tamoxifen duration (1997-2018)

AstraZeneca: £1.0M plus drug supply

BEST-D pilot trial of vitamin D (2012-2014)

Tishcon: free drug supply only

Big Data Institute (2018-2021)

Novartis Pharma AG Switzerland: £272K

Can wearables improve the prediction of all-cause mortality, cardiovascular disease, and cancer in UK Biobank? (2022-25)

Swiss Reinsurance Company: £645K

China Kadoorie Biobank (2002-ongoing)

AstraZeneca: $300K

Bayer AG: £300K

GlaxoSmithKline: £3.6M

Merck: £200K

Novo Nordisk A/S: £341k

Development of digital biomarkers for dementia (2016-2022)

Eli Lilly and Company USA: £600K

Development of digital biomarkers for dementia (2016-2022)

Roche: £600K

Diabetic Peripheral Neuropathy Treatment with Dorsal Root Ganglion Stimulation a Randomised Controlled Trial (2018-2020)

St Jude Medical Europe Inc: £52K

Doctor Referral of Overweight People to Low Energy Treatments (2015-2020)

Cambridge Weight Plan Ltd: £35K

DYNAMIC CONSENT USCF (2015-17)

Oxford University Innovation Ltd: £28K

EASi-KIDNEY. A multicentre international randomised double-blind placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in patients with chronic kidney disease treated with empagliflozin (2023-ongoing)

       Boehringer Ingelheim International GmbH: £182.3M

Economic burden of malignant neoplasms in the EU (2011-2012)

Pfizer: £36.5K

Elinogrel feasibility trial (2010-2011)

Novartis: £500K

EMPA-KIDNEY (2017-ongoing)

Boehringer Ingelheim: £106.3M

Establishing Fuwai-Oxford research centre (2010-ongoing)

Merck: £1.1M

Estimating acceptable non-inferiority margins for antibiotic stewardship interventions using discrete choice experiments (2021-2023)

Mars Petcare UK: £25k

EXSCEL trial of exenatide (2009-2017)

Amylin: £473K *

FOXFIRE trial of chemotherapy with or without radioembolisation for bowel cancer that has spread to the liver (2009-2017)

Sirtex: £228K *

Genomic Data Working Group (2020-2025)

Regeneron Pharmaceuticals Inc: £107K

Heart Protection Study follow-up studies (2003-2010)

Merck: £1.2M

GlaxoSmithKline: $400K

Liposcience: £50K

HPS2-THRIVE trial of niacin/laropiprant (2005-2015)

Merck: £53M plus drug supply

HPS3/TIMI55-REVEAL trial of anacetrapib (2010-2022)

Merck: £108M plus drug supply

HPS 4/TIMI 65 – ORION-4 (2017-ongoing)

Novartis Pharma AG Switzerland: £73.7M

HPS 5/ORION-17 (2020-ongoing)

Novartis Pharma AG Switzerland: £1M

Integration of medical imaging and genetic data using machine learning for identification of micro and macro vascular disease targets (2021 – ongoing)

Novo Nordisk A/S: £1.2M

Large-scale multi-omics assays in China Kadoorie Biobank (2020 – 2023)

Bayer AG: £1.58M

LENS trial in Non-proliferative retinopathy in Scotland (2016-2022)

Mylan: free drug supply only

MaatHRI Project (Ultromics) (2018-2022)

Ultromics Limited: £79K

Measuring sleep characteristics using machine learning in wearable datasets (2020-2023)

Novo Nordisk A/S: £135K

Mexico City Prospective Study (2021 – ongoing)

AstraZeneca UK Ltd: £1.81M

Regeneron Pharmaceuticals Inc: £1.78M

NAVIGATOR trial health economics analysis (2013-2014)

Novartis: £15K *

Next generation sequencing analysis - a clinical study (2011-2014)

Life Technologies: £125K *

Non-invasive rapid assessment of liver disease using magnetic resonance (2016-2019)

Perspectum Diagnostics: £273K *

Novo-Nordisk Postdoctoral Fellowship Programme (2021-2023)

Novo Nordisk A/S: £221.3K

Observational study of a multi-cancer early detection test (2021-2023)

Grail Bio UK Ltd: £101k

Oxford-Janssen Human Genomics Fellowship Programme (2020 – ongoing)

Janssen Biotech: 1.22M

Oxford Participation & Activities Questionnaire (Ox-PAQ) Phase 2 Study (2014-2017)

Actelion: £58K

OxPod (2021-27)

Podium Analytics: £75K

Pandemic Science Institute Investigator Allowance (2022-23)

AstraZeneca UK Ltd £5k

Pharmacogenomic analysis of the Heart Protection Study using a CAD polygenic risk score (2020 – 2025)

Regeneron Pharmaceuticals Inc: £143K

PROCARDIS genetic study (1998-2011)

AstraZeneca: £1.7M

SEARCH trial of simvastatin dose (1997-2010)

Merck: £22.7M plus drug supply

SHARP trial of simvasatin/ezetimibe (2002-2013)

Merck/Schering: £40M plus drug supply

SHARP3 (2022-23)

Boehringer Ingelheim: £1.8M

Small open reading frames in drug discovery: from genetics to mechanisms to new therapies (2022-24)